Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00246324
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2005-10-27
Brief Title:
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
Sponsor:
Louisiana State University Health Sciences Center Shreveport
Organization:
Louisiana State University Health Sciences Center Shreveport
Study Overview
Official Title:
An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis RRMS
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy safety and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline a potent inhibitor of matrix metalloproteinases in patients with relapsing remitting multiple sclerosis RRMS having breakthrough disease activity
Detailed Description:
Eligible individuals were evaluated monthly for 3 months while taking intramuscular interferon beta-1a 30 micrograms weekly then monthly for 4 months while receiving intramuscular interferon beta-1a 30 micrograms and oral doxycycline 100 mg daily
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None